actavis inc (ACT:New York)
Executive Profile*
Andrew L. TurnerNon Executive Chairman, Actavis, Inc. |
| Age | Total Calculated Compensation | This person is connected to 21 board members in 3 different organizations across 5 different industries. See Board Relationships |
| 65 | $375,972 |
Background*
Mr. Andrew L. Turner serves as the President of Rio Ranchito Inc. Mr. Turner is the Founder of Enduracare Therapy Management, Inc. He has held several executive management positions that span more than 30 years. He is Founder of Sun Healthcare Group Inc. and served as its Chief Executive Officer from 1989 to August 2000. He has been the Non-Executive Chairman of Actavis, Inc. (formerly Watson Pharmaceuticals, Inc.), since May 2008. He serves as Chairman of the Board ...
Corporate Headquarters*Morris Corporate Center IIIParsippany, New Jersey 07054 United States Phone: 862-261-7000 Fax: -- Board Members Memberships*Former Chairman 1994-Present Director, Chairman of Compensation Committee, Member of Audit Committee, Member of Nominating & Governance Committee and Member of Special Committee 1997-Present Non Executive Chairman 2006-Present Director, Chairman of Compensation Committee and Member of Audit Committee
Education*BA 1970 The Ohio State University
Other Affiliations* |
Annual Compensation*There is no Annual Compensation data available.Stock Options*There is no Stock Options data available.Total Compensation*
|
| Recently Viewed | |||
| ACT:US | $128.08 USD | -1.96 |  |
COMPETITOR COMPENSATION
| Name | Position/ Company | Compensation |
| Dilip Shantilal Shanghvi | Managing Director, Promoter executive Director and Member of Shareholders/Investors Grievance Committee Sun Pharmaceutical Industries Limited | -- |
| Heather Bresch | Chief Executive Officer, Director and Member of Science & Technology Committee Mylan, Inc. | $998.1K |
| J. Michael Pearson | Chairman and Chief Executive Officer Valeant Pharmaceuticals International, Inc. | $1.7M |
| Flemming Ornskov M.D., MBA, MPH | Chief Executive Officer, Head of Human Genetic Therapies and Director Shire plc | -- |
| Frederic Roch Doliveux DVM | Chief Executive Officer and Executive Director UCB SA | €1.8M | Compensation as of Fiscal Year --. |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ACTAVIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
